Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | ATR | Q13535 | 7/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720153 | 1.00 | HRH3 (0.49) | HRH3ATRVNN1SYKABL1 | |
| SCHEMBL3718939 | 1.00 | HRH3 (0.49) | HRH3ATRVNN1SYKABL1 | |
| SCHEMBL3726910 | 0.86 | GHSR (0.46) | SYKABL1BCR | |
| SCHEMBL3725223 | 0.85 | GHSR (0.45) | SYKABL1BCR | |
| SCHEMBL4174996 | 0.85 | GHSR (0.43) | SYKABL1BCR | |
| SCHEMBL4189501 | 0.85 | SYK (0.44) | SYKABL1BCR | |
| SCHEMBL3719497 | 0.85 | SYK (0.44) | HRH3SYKABL1BCR | |
| SCHEMBL4186173 | 0.85 | ABL1 (0.48) | SYKABL1BCR | |
| SCHEMBL3721814 | 0.84 | ACACB (0.46) | HRH3SYKABL1BCR | |
| SCHEMBL3722403 | 0.84 | CCNC (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | HRH3 453/4885ATR 2485/4885VNN1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.